Recent advancements in drug development for pulmonary tuberculosis
Archives of Microbiology · 2025
DOI: 10.1007/s00203-025-04415-y ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Archives of Microbiology, 2025. Verfasst von Koushik Mukherjee und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Kalyani Mahavidyalaya, City Centre Complex, Kalyani, Nadia, West Bengal, 741235, India. koushikmukh@gmail.com. Hauptthemen laut MEDLINE: Antitubercular Agents, Mycobacterium tuberculosis, Tuberculosis, Pulmonary, Drug Development. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 124 Literaturangaben.
Abstract (Originalsprache)
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is a global health threat. Despite advances in diagnostics and treatment regimens, it infects millions annually. It remains a significant global health challenge, particularly due to the appearance of resistance towards anti-tuberculosis drugs (ATD), mainly multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains. Mtb poses resistance towards the currently used first- and second-line regimen. Recent advancements in drug development have introduced therapeutic options focussed on improving treatment outcomes for both drug-sensitive and drug-resistant TB. This includes the implementation of a shorter 6-month regimen, a combination of bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM), and all-oral treatment regimens (nine months treatment) for patients with MDR/Rifampicin TB-resistance. Another longer 18-20-month regimen is also accessible for patients with TB resistance, for whom all other regimens or treatments are not feasible due to various factors. Ongoing research into new drug molecules, adjunct therapies, and advancement in faster diagnosis aims to enhance the efficacy and tolerability of TB treatment while tackling challenges related to adherence and resistance. This review will discuss the limitations of current treatment regimens, and recent developments in the pharmacological landscape of TB management, highlighting innovative strategies and the necessity for continued efforts to combat the evolving threat of this headstrong pathogen. The findings underscore the importance of a patient-centered approach in TB treatment to achieve equitable and sustainable health outcomes globally.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, Kalyani Mahavidyalaya, City Centre Complex, Kalyani, Nadia, West Bengal, 741235, India. koushikmukh@gmail.com.
- Department of Chemistry, Kalyani Mahavidyalaya, City Centre Complex, Kalyani, Nadia, West Bengal, 741235, India.
- Department of Microbiology, Michael Madhusudan Memorial College, Durgapur, West Bengal, 713216, India.
- Department of Microbiology, Kalyani Mahavidyalaya, City Centre Complex, Kalyani, Nadia, West Bengal, 741235, India.
Zitieren
APA
Mukherjee, K., Saha, P., Ganguly, K. K., Chakraborty, S., Ghosh, S., & Kundu, G. (2025). Recent advancements in drug development for pulmonary tuberculosis. Archives of Microbiology. https://doi.org/10.1007/s00203-025-04415-y
Vancouver
Mukherjee K, Saha P, Ganguly KK, Chakraborty S, Ghosh S, Kundu G. Recent advancements in drug development for pulmonary tuberculosis. Archives of Microbiology. 2025. doi:10.1007/s00203-025-04415-y
BibTeX
@article{Mukherjee2025,
author = {Mukherjee, Koushik and Saha, Pritam and Ganguly, Kirat Kumar and Chakraborty, Somjyoti and Ghosh, Swarnali and Kundu, Gopal},
title = {Recent advancements in drug development for pulmonary tuberculosis},
journal = {Archives of Microbiology},
year = {2025},
doi = {10.1007/s00203-025-04415-y}
}
EUVIMED